0.419

3.56% 0.0144

Acurx Pharmaceuticals Inc (ACXP)

Overview News Price History Option Chain Financials Discussions Forecast

Acurx Pharmaceuticals Inc stock is traded at $0.419, with a volume of 54,256. It is up +3.56% in the last 24 hours and up +2.60% over the past month. Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.

Previous Close:

$0.4046

Open:

$0.4051

24h Volume:

54,256

Relative Volume:

0.23

Market Cap:

$8.13M

Revenue:

Net Income/Loss:

$-14.58M

P/E Ratio:

-0.3643

EPS:

-1.15

Net Cash Flow:

$-9.80M

1W Performance:

+13.55%

1M Performance:

+2.60%

6M Performance:

-77.83%

1Y Performance:

-79.76%

1-Day Range:

$0.4046

$0.4304

1-Week Range:

$0.37

$0.4304

52-Week Range:

$0.30

$3.325

Acurx Pharmaceuticals Inc Stock (ACXP) Company Profile

Name

Acurx Pharmaceuticals Inc

Sector

Healthcare (1153)

Industry

Biotechnology (673)

Phone

917-533-1469

Address

259 LIBERTY AVENUE, STATEN ISLAND

Employee

Twitter

Next Earnings Date

2025-03-18

Latest SEC Filings

ACXP's Discussions on Twitter

Compare ACXP with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ACXP Acurx Pharmaceuticals Inc	0.419	8.13M	0	-14.58M	-9.80M	-1.15
VRTX Vertex Pharmaceuticals Inc	496.49	122.76B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	610.86	61.38B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	620.97	36.37B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	254.85	30.12B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	249.46	24.70B	3.81B	-644.79M	-669.77M	-6.24

Acurx Pharmaceuticals Inc Stock (ACXP) Latest News

Apr 28, 2025

Acurx CEO to Reveal Phase 3 Strategy for Breakthrough C. Difficile Antibiotic at Major Healthcare Conference - Stock Titan

Apr 28, 2025

Apr 17, 2025

Acurx Pharmaceuticals secures patent in India for antibiotics By Investing.com - Investing.com Canada

Apr 17, 2025

Acurx Pharmaceuticals secures patent in India for antibiotics - Investing.com

Apr 17, 2025

Acurx Expands Global Patent Portfolio: Phase 3-Ready Drug Targets MRSA, Anthrax, and Superbugs - Stock Titan

Apr 17, 2025

Indian Patent Office Grants Acurx Patent for DNA Polymerase IIIC Inhibitors - Yahoo Finance

Apr 17, 2025

Apr 16, 2025

Lobbying Update: $20,000 of ACURX PHARMACEUTICALS INC. lobbying was just disclosed - Nasdaq

Apr 16, 2025

New to The Street Renews Acurx Pharmaceuticals (NASDAQ: ACXP) for Exclusive 6-Month Media Series Including Nationwide TV, Earned Media, and Expanded Digital Reach - Corsicana Daily Sun

Apr 16, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 16, 2025

Apr 08, 2025

Acurx Pharmaceuticals (ACXP) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now - Yahoo Finance

Apr 08, 2025

Apr 06, 2025

Acurx Pharmaceuticals announces resale of 8.4M shares - MSN

Apr 06, 2025

Apr 02, 2025

10 Micro-Cap Stocks Insiders Were Buying in Q1 2025 - Insider Monkey

Apr 02, 2025